Drug Trial Radar · NCT05623774
A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Dec 16, 2022
Primary completion
Jun 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Inhibikase TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study investigates the safety, tolerability and dose equivalence of drug IkT-001Pro in healthy volunteers (18 to 55 years old) in comparison to imatinib mesylate. This study is designed in 3 parts. Part A consists of 3 cohorts. In cohort 1 healthy participants will take a single, oral dose of 400mg IkT-001Pro then will be followed by a single dose of 400mg Imatinib mesylate after a 7-day washout. Cohort 2 and 3 will follow the same structure as cohort 1 with a different Ikt-001Pro dose. Part B will be chosen using Part A data by statistical procedures. Part B will enroll 32 subjects to demonstrate the bioequivalence of IkT-001Pro (the 'Test') to 400 mg imatinib delivered as imatinib mesylase (the 'Reference'). Part C (Dose Equivalence at 600 mg): Part C will enroll up to eight (8) subjects to demonstrate bioequivalence of imatinib delivered as 800 mg IkT-001Pro (the 'Test') to 600 mg imatinib delivered as imatinib mesylate ('the Reference')
Conditions
- CML
Interventions
Imatinib MesylateDrug
400mg tablet
IkT-001ProDrug
100mg or 400mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exposure of imatinib after administration of IkT-001Pro and imatinib mesylate, as measured by area under the concentration-time curve for imatinib from time zero to last measurable concentration (AUC(0-last))Time frame: Day 1 through day 12
- Exposure of imatinib after administration of IkT-001Pro and imatinib mesylate, as measured by area under the concentration-time curve for imatinib from time zero to infinity (AUC0-inf)Time frame: Day 1 through day 12
- Exposure of imatinib after administration of IkT-001Pro and imatinib mesylate, as measured by the maximum plasma concentration (Cmax) of imatinibTime frame: Day 1 through day 12
- Safety: Incidence and temporal profile of treatment-emergent adverse events (TEAEs) evaluated by type/nature, severity/intensity, seriousness, and relationship to study interventionTime frame: Day 1 through day 12
- Safety: Proportion of those in each dosing cohort who discontinued the assigned regimenTime frame: Day 1 through day 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.